Omada Health is growing revenue rapidly with a perfect 4-quarter earnings beat streak, but the stock is technically overbought, has already exceeded its price target, and notable insider selling adds a cautionary signal.
Thesis pillars
- Strong Revenue Growth→Stable
- Overbought Late Cycle Risk↑Improving
- Notable Insider Selling→Stable
- +2 more pillars — see the Why tab for full reasoning
Omada Health, Inc. (OMDA) Stock Analysis
Catalyst-Driven edge
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $21.87, but acceptable to hold if already in. Reasons: Elevated risk factors; Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (25 sells, 0.26% of cap).
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal... Read more
Hold if already holding. Not a fresh buy at $21.87, but acceptable to hold if already in. Reasons: Elevated risk factors; Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (25 sells, 0.26% of cap). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.
Passes 5/7 gates (positive momentum, no SEC red flags, earnings proximity 23d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-10-13Recent Developments — Omada Health, Inc.
Latest news
- NEWS Quantinno Capital Management LP Grows Stock Position in Omada Health, Inc. $OMDA - MarketBeat — MarketBeat neutral
- NEWS AlpInvest Partners B.V. Makes New $1.18 Million Investment in Omada Health, Inc. $OMDA - MarketBeat — MarketBeat positive
- NEWS Omada Health (NASDAQ:OMDA) President Sells 8,866 Shares - MarketBeat — MarketBeat negative
- NEWS Omada Health (NASDAQ:OMDA) CAO Craig Gracey Sells 1,042 Shares of Stock - MarketBeat — MarketBeat negative
- NEWS Omada Health CFO Steven Cook sells $421k in stock - Investing.com — Investing.com negative
Generated 2026-10-13T11:32:15Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerlimited number of customers and channel partners10-K Item 1A: 'A substantial portion of our sales comes from or through a limited number of customers and channel partners that operate as resellers.'
- MEDIUMSupplierlimited number of third-party suppliers10-K Item 1A: 'We depend on a limited number of third-party suppliers for certain devices and other supplies that we deliver to members in connection with our programs'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $21.87, but acceptable to hold if already in. Reasons: Elevated risk factors; Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (25 sells, 0.26% of cap). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $24.72 (+13.0%), stop $20.34 (−7.5%), A.R:R 0.9:1. Score 6.1/10, moderate confidence.
Take-profit target: $24.72 (+13.0% upside). Target $24.72 (+13.0%), stop $20.34 (−7.5%), A.R:R 0.9:1. Stop-loss: $20.34.
Elevated risk factors; Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (25 sells, 0.26% of cap).
Omada Health, Inc. trades at a P/E of 91.1 (forward 39.3). TrendMatrix value score: 5.3/10. Verdict: Hold.
18 analysts cover OMDA with a consensus score of 4.0/5. Average price target: $28.
What does Omada Health, Inc. do?Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the...
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.